Earnings summaries and quarterly performance for INTUITIVE SURGICAL.
Executive leadership at INTUITIVE SURGICAL.
David Rosa
Detailed
Chief Executive Officer
CEO
Bob DeSantis
Detailed
Executive Vice President and Chief Strategy and Corporate Operations Officer
Brian Miller
Detailed
Executive Vice President and Chief Digital Officer
Gary Loeb
Detailed
Executive Vice President and Chief Legal and Compliance Officer
Henry Charlton
Detailed
Executive Vice President, Chief Commercial and Marketing Officer
Jamie Samath
Detailed
Executive Vice President, Chief Financial Officer and Head of Business Technology
Mark Brosius
Detailed
Senior Vice President and Chief Manufacturing and Supply Chain Officer
Myriam Curet
Detailed
Executive Vice President and Chief Medical Officer
Board of directors at INTUITIVE SURGICAL.
Amal Johnson
Detailed
Director
Amy Ladd
Detailed
Director
Craig Barratt
Detailed
Lead Independent Director
Gary Guthart
Detailed
Executive Chair of the Board
Jami Nachtsheim
Detailed
Director
Joseph Beery
Detailed
Director
Keith Leonard
Detailed
Director
Lewis Chew
Detailed
Director
Monica Reed
Detailed
Director
Sreelakshmi Kolli
Detailed
Director
Research analysts who have asked questions during INTUITIVE SURGICAL earnings calls.
David Roman
Goldman Sachs Group Inc.
6 questions for ISRG
Also covers: ABT, BAX, BDX +18 more
Travis Steed
Bank of America
6 questions for ISRG
Also covers: ABT, AXNX, BAX +19 more
Robert Marcus
JPMorgan Chase & Co.
5 questions for ISRG
Also covers: ABT, BAX, BDX +21 more
Adam Maeder
Piper Sandler Companies
4 questions for ISRG
Also covers: ABT, AXNX, EW +13 more
Frederick Wise
Stifel
4 questions for ISRG
Also covers: AORT, ATRC, AVNS +13 more
Larry Biegelsen
Wells Fargo & Company
3 questions for ISRG
Also covers: ABT, ALC, AXNX +24 more
Lawrence Biegelsen
Wells Fargo
3 questions for ISRG
Also covers: ABT, ALC, BAX +16 more
Patrick Wood
Morgan Stanley
2 questions for ISRG
Also covers: ALC, BDX, BLCO +17 more
Rick Wise
Stifel Financial Corp
2 questions for ISRG
Also covers: BDX, BSX, GEHC +8 more
Brandon Vazquez
William Blair & Company, L.L.C.
1 question for ISRG
Also covers: ALGN, CBLL, CVRX +16 more
Matthew Miksic
Barclays PLC
1 question for ISRG
Also covers: ABT, ATEC, BAX +15 more
Robbie Marcus
JPMorgan Chase & Co.
1 question for ISRG
Also covers: ABT, BAX, BDX +9 more
Ryan Zimmerman
BTIG
1 question for ISRG
Also covers: ALC, GEHC, GKOS +23 more
Recent press releases and 8-K filings for ISRG.
Intuitive Surgical reports Q3 earnings beat, raises 2025 outlook
ISRG
Earnings
Guidance Update
- Intuitive Surgical beat Q3 revenue and EPS expectations with $2.51 billion in revenue and $2.40 adjusted EPS.
- Installed 427 new da Vinci systems and saw a 52% increase in Ion platform procedures.
- Instruments and accessories sales climbed 20% to $1.52 billion, aided by over 80% production in Mexico.
- Raised 2025 procedure growth outlook to 17–17.5% and boosted adjusted gross margin forecast to 67–67.5%.
Oct 21, 2025, 10:19 PM
Intuitive Surgical reports Q3 2025 results
ISRG
Earnings
Guidance Update
- Revenue grew 23% year-over-year to $2.51 billion; pro forma operating margin was 39%, and pro forma EPS was $2.40
- Total procedures increased 20%, with Da Vinci procedures up 19% and Ion procedures up 52%; average system utilization rose 4% for multiport, 35% for SP, and 14% for Ion
- Placed 427 Da Vinci systems in Q3—240 Da Vinci 5 and 30 SP—and 50 Ion systems; Da Vinci installed base grew 13% to ~10,800 systems, and Ion base rose 30% to ~950 systems
- Updated 2025 guidance: Da Vinci procedure growth raised to 17–17.5%, pro forma gross margin to 67–67.5%, operating expense growth to 11–13%, and tax rate to 21–22%
Oct 21, 2025, 8:30 PM
Intuitive Surgical reports Q3 2025 results
ISRG
Earnings
Guidance Update
Revenue Acceleration/Inflection
- In Q3 2025 pro-forma revenue was $2.50 B, up 23% YoY, with pro-forma EPS of $2.40 (+30%); GAAP EPS was $1.95
- Worldwide procedures grew 20%, with da Vinci procedures up 19% and Ion procedures up 52%; da Vinci installed base +13% (to ~10,800), utilization +4%; Ion base +30% (to ~950), utilization +14%
- Capital placements included 427 da Vinci systems (+13%), of which 240 were da Vinci V, plus 30 SP systems and 50 Ion systems; ASP for purchased da Vinci was $1.6 M
- 2025 guidance was raised: da Vinci procedure growth 17–17.5%, pro-forma gross margin 67–67.5%, operating expense growth 11–13%, tax rate 21–22%
- Generated $736 M free cash flow, repurchased $1.9 B of shares, and ended Q3 with $8.4 B in cash and investments
Oct 21, 2025, 8:30 PM
Intuitive Surgical reports Q3 2025 earnings
ISRG
Earnings
- Intuitive Surgical delivered $2.51 billion in Q3 2025 revenue, up 23% year-over-year.
- Pro-forma gross margin was 68.0%, and pro-forma EPS came in at $2.40.
- Da Vinci procedure volume grew 19% Y/Y, with the installed base up 13%, and 427 new systems placed in the quarter.
- As of September 30, 2025, the worldwide installed base reached 10,763 systems, including 6,223 in the U.S..
Oct 21, 2025, 8:30 PM
Intuitive Surgical reports Q3 2025 earnings
ISRG
Earnings
Guidance Update
Share Buyback
- Intuitive posted $2.51 billion in Q3 revenue, up 23% year-over-year, with GAAP net income of $704 million ($1.95/share) and non-GAAP net income of $867 million ($2.40/share).
- Worldwide procedures rose 20%, driven by 19% growth in da Vinci and 52% growth in Ion, and the da Vinci installed base grew to 10,763 systems (+13%).
- The company placed 427 da Vinci systems (including 240 da Vinci 5 units) and 50 Ion systems in Q3, and repurchased 4.0 million shares for $1.92 billion.
- For full-year 2025, Intuitive expects da Vinci procedure growth of 17%–17.5%, non-GAAP gross margin of 67%–67.5%, and operating expense growth of 11%–13%.
Oct 21, 2025, 8:05 PM
Intuitive Surgical announces Q3 2025 earnings
ISRG
Earnings
Guidance Update
Share Buyback
- Q3 2025 revenue of $2.51 billion, up 23% year-over-year.
- GAAP net income of $704 million (diluted EPS $1.95) and non-GAAP net income of $867 million (non-GAAP EPS $2.40).
- Worldwide procedures grew 20%, with 427 da Vinci system placements (installed base 10,763, +13% y/y) and 50 Ion placements (installed base 954, +30% y/y).
- Repurchased 4.0 million shares for $1.92 billion in Q3 2025.
- 2025 outlook: da Vinci procedure growth of 17–17.5%, non-GAAP gross margin of 67–67.5%, and operating expense growth of 11–13%.
Oct 21, 2025, 8:03 PM
Intuitive Surgical expands Ion system with AI-powered navigation and advanced imaging
ISRG
Product Launch
- The FDA has cleared new software for the Ion endoluminal system, adding AI-powered enhanced navigation that corrects CT-to-body divergence in real time, improving biopsy accuracy.
- The update integrates advanced imaging features, including tomosynthesis with a standard 2D C-arm, to provide real-time imaging during procedures.
- Intuitive plans a limited U.S. launch of these features in 2025, followed by a broader U.S. rollout in 2026.
- As of June 30, 2025, there are over 900 Ion systems installed across 10 countries, supported by 100+ abstracts/publications and studies involving 2,000+ subjects.
Oct 8, 2025, 1:15 PM
Intuitive unveils real-time surgical insights for da Vinci 5
ISRG
Product Launch
- Intuitive introduced new software capabilities for its da Vinci 5 surgical platform—powered by 10,000× the computing power of the prior Xi model—including Force Gauge, In-Console Video Replay and Network CCM to enhance real-time decision-making and efficiency.
- The Force Gauge feature provides a speedometer-style display of real-time force (0–6.5 N) at the instrument tip, with early users reporting consistently lower tissue force during procedures.
- In-Console Video Replay enables surgeons to review earlier moments of an ongoing operation without leaving the console, while Network CCM permits remote deployment of software updates; all three features have received FDA 510(k) clearance.
Sep 12, 2025, 1:15 PM
Intuitive Surgical: US Surgical Robots Market to Reach $4.14 B by 2030
ISRG
- United States surgical robots market valued at $2.35 B in 2024, projected to reach $4.14 B by 2030 at a 9.85% CAGR.
- Oncology applications are a primary growth driver as robotic systems enhance precision and recovery in cancer surgeries.
- High capital costs (system price of $1 M–$2.5 M) plus maintenance and training expenses limit adoption in smaller and rural hospitals.
- Growing deployment in outpatient and ambulatory surgery centers is prompting development of compact, cost-efficient robotic platforms for same-day procedures.
Aug 1, 2025, 11:59 AM
Intuitive Surgical demonstrates transatlantic telesurgery
ISRG
New Projects/Investments
- Intuitive Surgical used its da Vinci 5 system to perform a transatlantic telesurgery between Peachtree Corners, Georgia and Strasbourg, France, enabling remote instrument control with force feedback over 4,000 miles.
- The procedure showcases the company’s telecollaboration suite, which includes telementoring, teleproctoring and dual console surgery to enhance clinical outcomes and reduce care costs.
- Recent regulatory approvals and the appointment of CEO David J. Rosa contributed to a 6% share price increase over the last quarter.
Jul 16, 2025, 1:34 PM
Quarterly earnings call transcripts for INTUITIVE SURGICAL.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more